Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/133612
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHolub, Katarzyna-
dc.contributor.authorBiete Solà, Albert-
dc.date.accessioned2019-05-21T16:54:31Z-
dc.date.available2019-05-21T16:54:31Z-
dc.date.issued2018-12-22-
dc.identifier.issn1471-2407-
dc.identifier.urihttp://hdl.handle.net/2445/133612-
dc.description.abstractBACKGROUND: Systemic inflammation has long been related with adverse survival outcomes in cancer patients, and its biomarkers, such as the Neutrophil-to-Lymphocyte Ratio (NLR), are recognized as poor prognostic indicators. However, the role of eosinophils in this field has been largely overlooked. Here, we describe two new pre-treatment biomarkers, expressed as Eosinophil-to-Lymphocytes Ratio (ELR) and Eosinophil*Neutrophil-to-Lymphocytes ratio (ENLR), and we analyse their impact on prognosis of endometrial cancer (EC) patients. METHODS: A total of 163 consecutive patients diagnosed with EC and treated with postoperative radiotherapy +/- chemotherapy in our institution from January 2011 to December 2015 were evaluated. The cohort was divided in two groups applying the cut-off value of 0.1 and 0.5 according to ROC curve for pre-treatment ELR and ENLR, respectively. After patients' stratification according to the ESMO-ESGO-ESTRO modified risk assessment, subgroup analyses were conducted. RESULTS: Higher values of ELR and ENLR were associated with worse OS (p = 0.004 and p = 0.010, respectively). On univariate analysis, the factors associated with shorter OS were ELR ≥ 0.1 (HR = 2.9, p = 0.017), ENLR ≥ 0.5 (HR = 3.0, p = 0.015), advanced FIGO stage (HR = 3.4, p = 0.007), endometrioid histology (HR = 0.26, p = 0.003) and ESMO-ESGO-ESTRO high-risk (HR = 10.2, p = 0.023). On multivariate Cox regression, higher ELR and ENLR were independently associated with a worse outcome adjusted for the standardly applied prognostic factors. CONCLUSIONS: Increased values of ELR and ENLR portend worse OS in EC, especially in patients classified by the ESMO-ESGO-ESTRO guidelines as a high-risk group. To our best knowledge, this is the first report describing eosinophils-related ratios as prognostic biomarkers in malignant tumours.-
dc.format.extent9 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherBioMed Central-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1186/s12885-018-5131-x-
dc.relation.ispartofBMC Cancer, 2018, vol. 18, num. 1, p. 1280-
dc.relation.urihttps://doi.org/10.1186/s12885-018-5131-x-
dc.rightscc-by (c) Holub, Katarzyna et al., 2018-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es-
dc.subject.classificationCàncer d'endometri-
dc.subject.classificationMarcadors tumorals-
dc.subject.classificationPronòstic mèdic-
dc.subject.otherEndometrial cancer-
dc.subject.otherTumor markers-
dc.subject.otherPrognosis-
dc.titleNew pre-treatment eosinophil-related ratios as prognostic biomarkers for survival outcomes in endometrial cancer-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec687099-
dc.date.updated2019-05-21T16:54:32Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid30577833-
Appears in Collections:Articles publicats en revistes (Fonaments Clínics)

Files in This Item:
File Description SizeFormat 
687099.pdf748.96 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons